Global Markets and Technologies for Advanced Drug Delivery Systems

The global market for advanced drug delivery systems is estimated to increase from $275.0 billion in 2022 to reach $376.8 billion by 2027, at a compound annual growth rate (CAGR) of 6.5% during the forecast period (2022-2027).

Report Includes

• 61 data tables and 61 additional tables
• An up-to-date review and comprehensive analysis of the global markets for advanced drug delivery systems (ADDS) and processes
• Analyses of the global market trends, with historic market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
• Highlights of the current state of the advanced drug delivery market, recent technologies and platforms, and market participants
• Estimation of the actual market size and market forecast for advanced drug delivery systems in value terms, and their corresponding market share analysis by technology, application, route of administration, vehicle/carrier of drugs mechanism, and geographic region
• Assessment of major growth drivers, opportunities and challenges in this innovation driven market, with an update on the COVID-19 impact on advanced drug delivery systems
• Review of patents and patent applications filed on drug delivery release mechanisms, clinical trial landscape, and emerging developments in the global market
• Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
• Descriptive company profiles of the advanced drug-device combination products manufacturers, including 3M Co., Abbott Laboratories, B. Braun Melsungen AG, BD, Boston Scientific Corp., Medtronic, Sanofi S.A., and Terumo Corp.

The global market for advanced drug delivery systems should grow from $231.0 billion in 2020 to $310.0 billion by 2025, at a compound annual growth rate (CAGR) of 6.1% for the period of 2020-2025.

Report Includes

• 62 data tables 62 additional tables
• An overview of the global markets and technologies for advanced drug delivery systems
• Analyses of global market trends, with data from 2018, 2019, estimates for 2020 and projections of compound annual growth rates (CAGRs) through 2025
• A look into the current state, setbacks, innovations, and future trends, and coverage of clinical trials in drug delivery systems
• Discussion on the different categories of drug delivery, and details of acquisitions, mergers, and alliances by companies and global organizations
• Description of advanced immediate-release technology and delayed release and pulsatile release drug delivery technology
• Information on monoclonal antibodies (MAbs), Prodrugs and other drug carriers of advanced drug delivery systems
• Insights of the regulatory environment, and the technology involved, including the latest trends and developments
• Company profiles of major players including Alcon, Bausch & Lomb, Baxter International Inc., Eisai Co. Ltd., GlaxoSmithKline PLC, Eli Lilly, Novartis and Sanofi

The global advanced drug delivery market should grow from roughly $178.8 billion in 2015 to nearly $227.3 billion by 2020, with a compound annual growth rate (CAGR) of 4.9%.

Report Includes

• An overview of the global market for drug delivery systems, including the market as seen by end users of different applications
• Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
• Discussion of the current state, setbacks, innovations, and the future needs of the market
• Examination of the different categories of drug delivery, broken down by market shares of the leading manufacturers and/or suppliers, as well as acquisitions, mergers, and alliances by companies and global organizations
• Analyses of the regulatory environment, and the technology involved, including the latest trends and developments
• Profiles of major players in the industry

The global revenue for advanced drug delivery systems is estimated to be $151.3 billion in 2013. In 2018,  revenues are estimated to reach nearly $173.8 billion, demonstrating a compound annual growth rate (CAGR) of 2.8%.

Report Includes

• An overview of the global market for drug delivery systems, including the market as seen by end users of different applications
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• Discussion of the current state, setbacks, innovations, and the future needs of the market
• Examination of the different categories of drug delivery, broken down by market shares of the leading manufacturers and/or suppliers, as well as acquisitions, mergers, and alliances by companies and global organizations
• Analyses of the regulatory environment, and the technology involved, including the latest trends and developments

The global market for drug delivery systems in 2010 was $131.6 billion and is expected to increase to $137.8 billion by the end of 2011. The market is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016.

• The global market for advanced drug delivery systems amounted to $134.3 billion in 2008, and was projected to increase to $139 billion in 2009. The estimate for 2014 is $196.4 billion, for a compound annual growth rate (CAGR) of 7.2% in the 5-year period.
• The largest segment of the market is targeted drug delivery, which reached $50.9 billion in 2009 and is expected to increase to $80.2 billion in 2014, for a CAGR of 9.5%.
• Sustained-release products have the second-largest market share, with estimated sales of $36.1 billion in 2009 and $45.8 billion in 2014, for a CAGR of 4.9%.

• The U.S. sales of advanced drug delivery systems were over $54.2 billion in 2004. In 2005 they reached $64.1 billion and will eventually grow to $74.4 billion by the end of 2006. Over 5 years, this market will continue to grow at an average annual growth rate (AAGR) of 15.6% to reach $153.5 billion by 2011.
• The largest sector of the market consists of sustained release/implants/transdermal drug delivery systems, with more than 50% of the total U.S. market in 2005. Through the forecast period this sector will gradually give way to targeted drug delivery systems, which should control almost 48% of the market in 2011.
• Targeted drug delivery has the highest growth rate, with a 23.3% AAGR through 2011. The next highest are transmucosal drug delivery systems, with 15.3%.

• The U.S. market for drug delivery systems in 2002 was $38.8 billion, and is expected to rise at an average annual growth rate (AAGR) of 11.3% and reach $74.5 billion by 2008.
• The sustained release (oral, injectable and topical) dosage form market is rising at an AAGR of 9.7% is expected to reach $34.1 billion by 2008.
• The transmucosal market is expected to grow at an AAGR of 12.8% and reach $17.7 billion by 2008.
• The market for targeted delivery systems was $7.3 billion in 2002 and will reach $15.5 billion by 2008.
• Transdermal systems and implants and IUDs are expected to climb at AAGRs of 11.1% and 12.4%, respectively.

• Despite the complaints of health care being too expensive, the U.S. pharmaceutical industry is expected to offer increasing opportunities for advanced drug delivery systems, with the U.S. market for the systems estimated at $16.3 billion in 2000. The efficacy, safety, and convenience of the technologies should maintain average annual growth of 10.9% over the next five years, when sales are predicted to be about $27.4 billion.
• At $13.8 billion in estimated 2000 manufacturers' sales, standard controlled release technologies (microencapsulation, polymer/membrane, and coatings) dominate the market for advanced drug delivery systems. The intense competition in generic products is stimulating growth (7.2%), especially in oral formats, both osmotic and microencapsulated. Demand for injected sustained release products is also spurring growth. The widespread interest in controlled released systems should result in sales reaching $19.6 billion in five years.